Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TYMS | P04818 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7784325 | 0.87 | ALDH1A1 (0.50) | ALDH1A1CYP3A4CTSBMAPTSMN1; SMN2 | |
| SCHEMBL7787972 | 0.82 | ALDH1A1 (0.59) | ALDH1A1CYP3A4CTSBMAPTSMN1; SMN2 | |
| SCHEMBL29617721 | 0.82 | TDP1 (0.44) | ALDH1A1CYP3A4CTSBMAPTTDP1 | |
| SCHEMBL602423 | 0.82 | TDP1 (0.53) | ALDH1A1CYP3A4CTSBMAPTSMN1; SMN2 | |
| SCHEMBL2132590 | 0.82 | TDP1 (0.44) | ALDH1A1CYP3A4CTSBMAPTTDP1 | |
| SCHEMBL29706644 | 0.79 | ALDH1A1 (0.68) | ALDH1A1CYP3A4CTSBMAPTSMN1; SMN2 | |
| SCHEMBL2783704 | 0.79 | ALDH1A1 (0.68) | ALDH1A1CYP3A4CTSBMAPTSMN1; SMN2 | |
| SCHEMBL18496986 | 0.79 | ATM (0.48) | ALDH1A1CYP3A4MAPTSMN1; SMN2TDP1 | |
| SCHEMBL4704860 | 0.78 | ALDH1A1 (0.43) | ALDH1A1CYP3A4CTSBMAPTSMN1; SMN2 | |
| SCHEMBL3296412 | 0.78 | ALDH1A1 (0.47) | ALDH1A1CYP3A4CTSBMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186425-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. | 2025-06-12 | — | — | US | disclosed |
| EP-4219460-B1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA INC (US) | 2025-02-26 | — | — | EP | disclosed |
| EP-4490147-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | Flare Therapeutics Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20250011324-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC., | 2025-01-09 | — | — | US | disclosed |
| US-12152026-B2 | Transglutaminase 2 (TG2) inhibitors | SITARI PHARMA, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| CN-118984823-A | PPARG inverse agonists and uses thereof | 弗拉雷治疗公司 | 2024-11-19 | — | — | CN | disclosed |
| WO-2024026419-A1 | QUINOXALINE DERIVATIVES AS PIK3 ALPHA MODULATORS | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2023172845-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| EP-4219460-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | Sitari Pharma, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023118267-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2023-06-29 | — | — | WO | disclosed |
| EP-0647137-A1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-04-12 | — | — | EP | disclosed |
| EP-0501378-B1 | NMDA Antagonists | MERRELL DOW PHARMA (US) | 1995-01-11 | — | — | EP | disclosed |
| US-5360814-A | NMDA antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-11-01 | — | — | US | disclosed |
| EP-0405525-B1 | Novel cyanoguanidine derivatives | KANEBO LTD (JP) | 1994-09-14 | — | — | EP | disclosed |
| WO-1994000124-A1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | WEBER ECKARD (US) | 1994-01-06 | — | — | WO | disclosed |
| EP-0573562-A1 | NMDA ANTAGONISTS. | MERRELL DOW PHARMA (US) | 1993-12-15 | — | — | EP | disclosed |
| WO-1992015565-A1 | NMDA ANTAGONISTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-09-17 | — | — | WO | disclosed |
| EP-0501378-A1 | NMDA Antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-09-02 | — | — | EP | disclosed |
| US-5087640-A | Potassium channel openers; hypotensive agents, coronary vasodilators | KANEBO, LTD. (JP) | 1992-02-11 | — | — | US | disclosed |
| EP-0405525-A2 | Novel cyanoguanidine derivatives | KANEBO, LTD. (JP) | 1991-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186425-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | PPARG, PPARA, PPARD | ALDH1A1 1455/4885CYP3A4 628/4885CTSB 2648/4885 |
| US-12152026-B2 | Transglutaminase 2 (TG2) inhibitors | TGM2, TGM3, TGM1 | ALDH1A1 4148/4885CYP3A4 3514/4885CTSB 321/4885 |
| US-20250011324-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | TGM2, TGM3, TGM1 | ALDH1A1 4148/4885CYP3A4 3514/4885CTSB 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.